多西紫杉醇联合唑来膦酸对激素难治性前列腺癌患者疗效及预后的影响(1)
[摘要] 目的 探讨多西紫杉醇联合唑来膦酸对激素难治性前列腺癌(HRPC)患者疗效及预后的影响。 方法 选择2015年11月～2016年11月在解放军第174医院就诊的HRPC患者92例，按照随机数字表法将其分为对照组与观察组，每组各46例。对照组采用多西紫杉醇静脉滴注治疗，观察组在对照组基础上加用100 mL唑来膦酸5%葡萄糖注射液或0.9%氯化钠注射液稀释后静脉滴注治疗。比较两组治疗效果、毒副作用发生情况。采用癌症生存质量量表(EROTC-QLQ-C30)对两组患者的生存质量进行评价。 结果 观察组总有效率明显高于对照组，毒副作用总发生率显著低于对照组，差异均有统计学意义(P < 0.05)。观察组癌症EROTC-QLQ-C30各功能量表评分、症状领域评分、单一项目评分及总体评分均明显高于对照组，差异有统计学意义(P < 0.05)。结论 多西紫杉醇联合唑来膦酸治疗HRPC毒副作用小，临床效果较好，且可明显改善患者的生存质量，是一种安全有效的治疗方法。
[关键词] 激素难治性前列腺癌；多西紫杉醇；唑来膦酸；疗效
[中图分类号] R697.3 [文献标识码] A [文章编号] 1673-7210(2017)12(c)-0076-04
[Abstract] Objective To explore the influence of Docetaxel combined with Zoledronic Acid on curative effect and prognosis of patients with hormone refractory prostate cancer (HRPC). Methods From November 2015 to November 2016， 92 cases of patients with HRPC treated in No. 174 Hospital of PLA were selected and divided into the control group and the observation group according to random number table， with 46 cases in each group. The control group was treated with intravenous drip of Docetaxel and the observation group was given intravenous drip of Zoledronic Acid 100mL which diluted by 5% glucose injection or 0.9% sodium chloride injection on the bases of control group. The total effective rate and the incidence of adverse reactions in the two groups were compared between the two groups. The European organization for research and treatment questionnaire of cancer quality of life questionnaire core 30 (EROTC-QLQ-C30) was used to assess the life quality of patients in the two groups. Results The total effective rate in the observation group was significantly higher than that of the control group， the incidence of adverse reactions was significantly lower than that of the control group， with statistically significant differences (P < 0.05). The scores of each work energy， symptom， single item and total score of EROTC-QLQ-C30 in the observation group were all significantly higher than those of the control group， with statistically significant differences (P < 0.05). Conclusion Docetaxel combined with Zoledronic Acid in the treatment of HRPC have low side effect and better clinical effect. It can significantly improve life quality of patients. It is a safe and effective treatment method.
[Key words] Hormone refractory prostate cancer； Docetaxel； Zoledronic acid； Curative effect
前列腺癌是男性常見的一种泌尿系统恶性肿瘤，临床多采用抗雄激素内分泌治疗，但经18～24个月治疗后，多数患者会对雄激素产生非依赖情况，不仅使该方法失去原有疗效，还可进一步发展为激素难治性前列腺癌(hormone refractory prostate cancer，HRPC)[1]。HRPC是前列腺癌发展过程中最为严重的阶段，患者普遍生存质量不高，且通常只有10～12个月的生存期，因此，探寻一种更为有效的HRPC治疗方法，对患者预后有重要意义。化疗是治疗HRPC的主要方法，多项研究结果显示[2-3]，多西紫杉醇联合唑来膦酸在前列腺癌治疗中效果显著，且毒副作用较小，能够有效提高患者的生活质量。本研究采用多西紫杉醇联合唑来膦酸对HRPC患者进行治疗，取得了满意效果。现报道如下：, 百拇医药(吴勇智 陈世伟)
[关键词] 激素难治性前列腺癌；多西紫杉醇；唑来膦酸；疗效
[中图分类号] R697.3 [文献标识码] A [文章编号] 1673-7210(2017)12(c)-0076-04
[Abstract] Objective To explore the influence of Docetaxel combined with Zoledronic Acid on curative effect and prognosis of patients with hormone refractory prostate cancer (HRPC). Methods From November 2015 to November 2016， 92 cases of patients with HRPC treated in No. 174 Hospital of PLA were selected and divided into the control group and the observation group according to random number table， with 46 cases in each group. The control group was treated with intravenous drip of Docetaxel and the observation group was given intravenous drip of Zoledronic Acid 100mL which diluted by 5% glucose injection or 0.9% sodium chloride injection on the bases of control group. The total effective rate and the incidence of adverse reactions in the two groups were compared between the two groups. The European organization for research and treatment questionnaire of cancer quality of life questionnaire core 30 (EROTC-QLQ-C30) was used to assess the life quality of patients in the two groups. Results The total effective rate in the observation group was significantly higher than that of the control group， the incidence of adverse reactions was significantly lower than that of the control group， with statistically significant differences (P < 0.05). The scores of each work energy， symptom， single item and total score of EROTC-QLQ-C30 in the observation group were all significantly higher than those of the control group， with statistically significant differences (P < 0.05). Conclusion Docetaxel combined with Zoledronic Acid in the treatment of HRPC have low side effect and better clinical effect. It can significantly improve life quality of patients. It is a safe and effective treatment method.
[Key words] Hormone refractory prostate cancer； Docetaxel； Zoledronic acid； Curative effect
前列腺癌是男性常見的一种泌尿系统恶性肿瘤，临床多采用抗雄激素内分泌治疗，但经18～24个月治疗后，多数患者会对雄激素产生非依赖情况，不仅使该方法失去原有疗效，还可进一步发展为激素难治性前列腺癌(hormone refractory prostate cancer，HRPC)[1]。HRPC是前列腺癌发展过程中最为严重的阶段，患者普遍生存质量不高，且通常只有10～12个月的生存期，因此，探寻一种更为有效的HRPC治疗方法，对患者预后有重要意义。化疗是治疗HRPC的主要方法，多项研究结果显示[2-3]，多西紫杉醇联合唑来膦酸在前列腺癌治疗中效果显著，且毒副作用较小，能够有效提高患者的生活质量。本研究采用多西紫杉醇联合唑来膦酸对HRPC患者进行治疗，取得了满意效果。现报道如下：, 百拇医药(吴勇智 陈世伟)